Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Outside the Lab Hematology, Screening and monitoring

Troponin at the Heart of it

“It is well established that high-sensitivity cardiac troponin concentrations can predict cardiovascular events, but it is not clear to clinicians how we can use this information to guide patient care,” says Nicholas Mills, Chair of Cardiology at The University of Edinburgh.

Eager to seek out the full benefit of the metric’s clinical potential, Mills acquired funding from the British Heart Foundation to lead an investigation to determine whether cardiac troponin I (cTnI) concentrations could predict cardiovascular risk or identify those healthy individuals who would benefit most from statin therapy.

In the study, Mills and his colleagues used novel, highly sensitive assays to measure cTnI levels in patients’ plasma and found that increased concentration suggested an elevated risk of coronary heart disease (1) – but that’s not all. The team also discovered that the protein may be a better indicator of statin therapy effects than standard cholesterol measurements. “Perhaps our most important observation was that troponin concentrations are reduced by statin therapy,” Mills says. “And individuals who have the greatest reduction in troponin have the lowest risk of coronary heart disease.” According to Mills, the absolute reduction in risk with statin therapy was threefold greater in men with hs-cTnI concentrations over 5 ng/L than in those below 5 ng/L. “In clinical practice we repeatedly measure cholesterol after initiating treatment. But our observations suggest that we should be tracking response to treatments for the prevention of coronary heart disease with high-sensitivity cardiac troponin I measurements,” says Mills.

In fact, he believes that cardiac troponin concentration has the potential to become the gold standard for predicting heart disease risk – and for tracking statin effectiveness, but notes that more work needs to be done: “We need to determine whether similar changes occur in women and in populations with coronary heart disease, and to determine whether a risk stratification threshold of 5 ng/L can also be applied to these populations.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. I Ford et al., “High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease”, J Am Coll Cardiol, 68, 2719-2728 (2016). PMID: 28007133.
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Related Application Notes
ClearLLab 10C Panel Markers and how they are combined

| Contributed by Beckman Coulter Life Sciences

ClearLLab Control Cells - A Process Control for ClearLLab 10C Application

| Contributed by Beckman Coulter Life Sciences

The Analysis of FFPE Samples by Next-Generation Sequencing (NGS) of Key Genes for Research into Breast and Ovarian Cancer

| Contributed by Oxford Gene Technology

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register